Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Ampio Pharmaceuticals, Inc. stock logo
AMPE
Ampio Pharmaceuticals
$0.00
-73.0%
$0.02
$0.00
$0.13
$3K4.76707 shs574 shs
NOVNQ
NVN Liquidation
$0.00
$0.00
$1.38
$22K1.6713,748 shsN/A
Scopus BioPharma Inc. stock logo
SCPS
Scopus BioPharma
$0.00
$0.00
$0.00
$0.01
$13K-0.191,931 shs688 shs
Vaxxinity, Inc. stock logo
VAXX
Vaxxinity
$0.00
$0.01
$0.00
$0.37
$13K-23.964,763 shs4,114 shs
7 Stocks to Buy And Hold Forever Cover

Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Ampio Pharmaceuticals, Inc. stock logo
AMPE
Ampio Pharmaceuticals
-73.00%+2,600.00%0.00%+28.57%-93.25%
NOVNQ
NVN Liquidation
0.00%0.00%0.00%0.00%0.00%
Scopus BioPharma Inc. stock logo
SCPS
Scopus BioPharma
0.00%0.00%-97.00%0.00%+50.00%
Vaxxinity, Inc. stock logo
VAXX
Vaxxinity
0.00%0.00%0.00%-50.00%-99.90%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Ampio Pharmaceuticals, Inc. stock logo
AMPE
Ampio Pharmaceuticals
N/AN/AN/AN/AN/AN/AN/AN/A
NOVNQ
NVN Liquidation
N/AN/AN/AN/AN/AN/AN/AN/A
Scopus BioPharma Inc. stock logo
SCPS
Scopus BioPharma
N/AN/AN/AN/AN/AN/AN/AN/A
Vaxxinity, Inc. stock logo
VAXX
Vaxxinity
N/AN/AN/AN/AN/AN/AN/AN/A
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Ampio Pharmaceuticals, Inc. stock logo
AMPE
Ampio Pharmaceuticals
0.00
N/AN/AN/A
NOVNQ
NVN Liquidation
0.00
N/AN/AN/A
Scopus BioPharma Inc. stock logo
SCPS
Scopus BioPharma
0.00
N/AN/AN/A
Vaxxinity, Inc. stock logo
VAXX
Vaxxinity
0.00
N/AN/AN/A
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Ampio Pharmaceuticals, Inc. stock logo
AMPE
Ampio Pharmaceuticals
N/AN/AN/AN/A$4.04 per shareN/A
NOVNQ
NVN Liquidation
$23.68M0.00N/AN/A$0.19 per share0.00
Scopus BioPharma Inc. stock logo
SCPS
Scopus BioPharma
N/AN/AN/AN/AN/AN/A
Vaxxinity, Inc. stock logo
VAXX
Vaxxinity
N/AN/AN/AN/A$0.11 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Ampio Pharmaceuticals, Inc. stock logo
AMPE
Ampio Pharmaceuticals
-$8.63M-$11.01N/AN/AN/AN/AN/AN/A
NOVNQ
NVN Liquidation
-$31.31M-$1.32N/AN/AN/AN/AN/AN/AN/A
Scopus BioPharma Inc. stock logo
SCPS
Scopus BioPharma
-$11.61MN/A0.00N/AN/AN/AN/AN/A
Vaxxinity, Inc. stock logo
VAXX
Vaxxinity
-$56.93M-$0.45N/AN/AN/AN/AN/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Ampio Pharmaceuticals, Inc. stock logo
AMPE
Ampio Pharmaceuticals
N/AN/AN/AN/AN/A
NOVNQ
NVN Liquidation
N/AN/AN/AN/AN/A
Scopus BioPharma Inc. stock logo
SCPS
Scopus BioPharma
N/AN/AN/AN/AN/A
Vaxxinity, Inc. stock logo
VAXX
Vaxxinity
N/AN/AN/AN/AN/A

Institutional Ownership

CompanyInstitutional Ownership
Ampio Pharmaceuticals, Inc. stock logo
AMPE
Ampio Pharmaceuticals
5.73%
NOVNQ
NVN Liquidation
N/A
Scopus BioPharma Inc. stock logo
SCPS
Scopus BioPharma
N/A
Vaxxinity, Inc. stock logo
VAXX
Vaxxinity
82.95%

Insider Ownership

CompanyInsider Ownership
Ampio Pharmaceuticals, Inc. stock logo
AMPE
Ampio Pharmaceuticals
3.30%
NOVNQ
NVN Liquidation
1.30%
Scopus BioPharma Inc. stock logo
SCPS
Scopus BioPharma
5.10%
Vaxxinity, Inc. stock logo
VAXX
Vaxxinity
64.06%
CompanyEmployeesShares OutstandingFree FloatOptionable
Ampio Pharmaceuticals, Inc. stock logo
AMPE
Ampio Pharmaceuticals
201.14 million1.10 millionNo Data
NOVNQ
NVN Liquidation
9028.01 million27.65 millionNo Data
Scopus BioPharma Inc. stock logo
SCPS
Scopus BioPharma
942.08 million39.94 millionNot Optionable
Vaxxinity, Inc. stock logo
VAXX
Vaxxinity
90126.75 million45.55 millionNot Optionable

Recent News About These Companies

Brain health
Treatment Trials in Alzheimer's Disease
Is Vaxxinity Inc (VAXX) Stock a Good Investment?
Why Is Vaxxinity (VAXX) Stock Up 39% Today?
Why Is Vaxxinity (VAXX) Stock Down 58% Today?
Vaxxinity Plans to Delist Shares From Nasdaq
Vaxxinity Issues Shareholder Letter
VAXX Stock Earnings: Vaxxinity Beats EPS for Q4 2023
Vaxxinity, UF Join Forces Against Neurodegenerative Diseases

New MarketBeat Followers Over Time

Ampio Pharmaceuticals stock logo

Ampio Pharmaceuticals NYSE:AMPE

$0.0027 -0.01 (-73.00%)
As of 02:57 PM Eastern

Ampio Pharmaceuticals, Inc., a biopharmaceutical company, develops therapies for the treatment of osteoarthritis of the knee (OAK) in the United States. It develops OA-201, a small molecule formulation for the treatment of OAK pain. The company is headquartered in Englewood, Colorado.

NVN Liquidation NASDAQ:NOVNQ

NVN Liquidation, Inc., a medical dermatology company, focuses on developing and commercializing therapeutic products for skin diseases. Its clinical stage dermatology drug candidates include SB204, a topical monotherapy for the treatment of acne vulgaris; SB206, a topical anti-viral gel for the treatment of viral skin infections; SB208, a topical broad-spectrum anti-fungal gel for the treatment of fungal infections of the skin and nails, including athlete's foot and fungal nail infections; and SB414, a topical cream-based gel product candidate for the treatment of inflammatory skin diseases. The company develops SB207, an anti-viral product candidate for the treatment of external genital warts; WH602, a nitric oxide-containing intravaginal gel to treat high-risk human papilloma virus (HPV); WH504, a non-gel formulation product candidate to treat high-risk HPV; and SB019 for the treatment of SARS-CoV-2. NVN Liquidation, Inc. has a license agreement with Sato Pharmaceutical Co., Ltd.; and a strategic alliance with Orion Corporation. The company was formerly known as Novan, Inc. and changed its name to NVN Liquidation, Inc. in October 2023. The company was incorporated in 2006 and is headquartered in Durham, North Carolina. On July 17, 2023, NVN Liquidation, Inc., along with its affiliate, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware.

Scopus BioPharma stock logo

Scopus BioPharma NASDAQ:SCPS

$0.0003 0.00 (0.00%)
As of 07/21/2025 09:37 AM Eastern

Scopus BioPharma Inc., a clinical-stage biopharmaceutical company, focuses on developing transformational therapeutics targeting serious diseases with unmet medical needs. It offers Duet Platform, which consists of signal transducer and activator of transcription 3 (STAT3), a master immune checkpoint inhibitor and toll-like receptor 9 (TLR9), as well as includes CpG-STAT3ASO (DUET-02), CpG-STAT3siRNA (DUET-01), and CpG-STAT3decoy (DUET-03); and that develops a suite of bifunctional oligonucleotides that activate antigen-presenting cells (APCs) in the tumor microenvironment that alleviates tumor immunosuppression to jump-start T cell-mediated immune responses. The company is also developing DUET-01, as a monotherapy targeting B-cell non-Hodgkin lymphoma; DUET-02 that provides systemic delivery for treatment of solid tumors comprising prostate or kidney cancers; and DUET-03, which targets the actual STAT3 transcription factor protein. Scopus BioPharma Inc. has licensing agreements with the City of Hope, National Institutes of Health Program, and The Hebrew University of Jerusalem. The company was formerly known as Project18 Inc. and changed its name to Scopus BioPharma Inc. in December 2017. Scopus BioPharma Inc. was incorporated in 2017 and is headquartered in New York, New York.

Vaxxinity stock logo

Vaxxinity NASDAQ:VAXX

$0.0001 0.00 (0.00%)
As of 07/21/2025 03:02 PM Eastern

Vaxxinity, Inc., a biotechnology company, focuses on developing product candidates for human use in the fields of neurology, cardiovascular diseases, and coronaviruses in the United States. Its product pipeline comprises UB-311, which is in phase 2 clinical trial that targets toxic forms of aggregated amyloid-b in the brain to fight alzheimer's disease; UB-312, which is in phase 1 clinical trial that targets toxic forms of aggregated a-synuclein in the brain to fight parkinson's disease and other synucleinopathies, such as Lewy body dementia and multiple system atrophy; and VXX-301, which is in preclinical trial, an anti-tau product candidate for various neurodegenerative conditions, including alzheimer's disease, traumatic brain injury, and chronic traumatic encephalopathy. It also develops VXX-401, which is phase 1 clinical trial that targets proprotein convertase subtilisin/kexin type 9 serine protease to lower low-density lipoprotein cholesterol and reduce the risk of cardiac events; UB-313 that targets calcitonin gene-related peptide to fight migraines; and UB-612, neutralizes the SARS-CoV-2 virus and is in phase 3 clinical trial. The company was incorporated in 2021 and is headquartered in Merritt Island, Florida.